Aims: Alcoholic liver disease (ALD) is now a well-recognized indication for liver transplantation. This paper reviews existing literature on living donor liver transplantation (LDLT) for ALD and presents data from a single, high volume United States liver transplant center. Methods: For the literature review, a PubMed search was undertaken using the search terms 'living donor' and 'alcoholic liver disease'. Studies were included that presented outcome data for patients who underwent LDLT for ALD. For the single-center data collection, all patients who underwent LDLT from 2003 to 2016 at our center were reviewed and the data for recipients with ALD was subsequently analyzed and compared with those patients who underwent LDLT for other indications. Results: Of 110 studies that resulted from the PubMed query, only 5 contained data that was relevant to this manuscript. These studies represented data collected from two Asian countries: one single center in Korea and a collection of centers in Japan. The relapse rate following LDLT for ALD ranged from 7.9% to 22%, and pre-transplant abstinence did not impact post-transplant relapse in any of these studies. For the single-center data, of 136 LDLT performed at our institution during the time period, 22 were performed for ALD. There was no difference in 1-or 5-year survival between patients transplanted for ALD and those transplanted for other etiologies (94.7% vs. 93.4%, P = 0.79 and 78.9% vs. 87.5%, P = 0.6). Conclusion: There is a very limited amount of data available on LDLT for ALD. Existing data suggests that LDLT for ALD results in excellent outcomes. Short Summary: Published data on living donor liver transplantation (LDLT) for alcoholic liver disease (ALD) are limited. One-and five-year survival rates range from 82% to 100% and 78% to 87%, respectively. Rates of alcohol relapse following transplant appear low, ranging from 7% to 23%; 6-month abstinence periods prior to LDLT for ALD do not appear to have a significant impact on relapse.
INTRODUCTION
Liver transplantation (LT) is the optimal therapy for patients with end-stage and chronic liver disease, patients with hepatocellular carcinoma limited in size and confined within the liver, and for patients with acute liver failure without the chance for recovery. Though there were early concerns regarding recipient outcome and the use of a limited resource in the event of potential relapse, alcoholic liver disease (ALD) is now a well-recognized indication for LT and results in excellent patient outcomes that are comparable to LT outcomes for other etiologies (Starzl et al., 1988; Belle et al., 1997; Pereira and Williams, 1997) .
Despite these results, the concept of LT for ALD still generates controversy among both the general population and physicians for several reasons (Perut et al., 2009; Neuberger and Webb, 2010) . First, many believe that patients should have a personal responsibility for their health and would classify ALD as a self-inflicted disease process that should lower these patients' priority to receive a limited resource (Singhvi et al., 2016) . On the other hand, others argue that the 6-month abstinence period required for patients with a history of alcohol abuse places them under higher scrutiny and potentially threatens their mortality, disrupting the ethical pillar of justice in transplantation (Singhvi et al., 2016) . And third, though addiction is an established medical condition, the possibility of relapse of alcohol consumption, often termed 'relapse', is particularly concerning when considering the allocation of a limited resource. The rates of relapse following LT are widely variable, with reports in the literature ranging anywhere from 7% to 95% (Lim and Keeffe, 2004; Bjornsson et al., 2005) . This variability is due to inconsistencies in definition, follow up, and reporting. Many, if not all, transplant centers require complete cessation of alcohol consumption following transplant. However, the classification of relapse/consumption remains heavily debated. Some groups consider any episodes of alcohol consumption to represent relapse, while others are concerned with alcohol consumption that negatively impacts morbidity and mortality. Still others consider return to other substances such as tobacco, marijuana, etc., and loss to follow up as part of the definition.
More recently, the question of whether LT might be indicated and effective in patients with acute on chronic decompensation associated with alcoholic hepatitis has arisen. In highly selected patients, outcome with deceased donor liver transplantation was superior to conventional therapy for fulminant hepatic failure due to alcohol. But at the core of all of these issues is the ethical dilemma of appropriately allocating a limited resource: deceased donor organs.
LIVING DONOR LIVER TRANSPLANTATION
The first successful adult-to-adult living donor liver transplantation (LDLT) was performed in 1993 in Japan using a left lobe graft (Ichida et al., 1995) , and over the past two decades, more than 10,000 LDLTs have been performed worldwide (Fan, 2011) . With LDLT, recipients have a shorter time to transplant, improved waitlist mortality (Roll et al., 2013) , and similar survival rates 5 years after transplant (83%) (Berg et al., 2011) when compared with recipients of deceased donor grafts. LDLT comprises more than 80% of the liver transplants performed throughout Asia, where deceased donor transplantation is generally not culturally acceptable and was developed in only a handful of countries (Fan, 2011) . Conversely, in the United States (US), LDLT accounts for just 4% of liver transplants, with only eight US transplant centers performing ≥10 LDLT each year (Kim and Testa, 2016) .
The concept of double equipoise for LDLT was first proposed in 2001 (Cronin et al., 2001) , reflecting the need to balance the risks and benefits for both the donors and recipients. As the transplant community has accrued experience with LDLT, the benefits to recipients have become well established, but it has also become increasingly clear that donors face a psychologically complex decision when faced with the opportunity to donate (Beresford, 2014) , take on a mortality risk of 0.1-1% (Roll et al., 2013) and experience post-operative complications at rates as high as 60%. However, as many of the issues surrounding LT for ALD concern the ethical allocation of a limited number of deceased donor grafts, it has been proposed that these issues might be mitigated through the use of organs from living donors (Singhvi et al., 2016) . According to Singhvi et al., '[adult LDLT] upholds ethical values: it supports equity in patients' access to LT (justice), might improve recipient outcomes (beneficence), and increases the number of organs available for LT, a strategic priority of the OPTN/UNOS' (Singhvi et al., 2016) .
LDLT FOR ALD-REVIEW OF EXISTING LITERATURE
There are currently few reports in the literature regarding the use and outcomes of LDLT for ALD, and the literature that does exist is from centers in Korea and Japan.
In (Hwang et al., 2006) . The purpose of this study was to examine the effect of a 6-month abstinence period on recipients of LDLT given that this is the typical abstinence period required for cadaveric liver transplant candidates. Of the 15 patients who underwent LDLT for ALD, 4 did not meet the 6-month abstinence rule. Eleven patients received single grafts, and all transplants were performed with living-related donors. One-year patient survival was 100% and 5-year patient survival was 87.5%. Three patients (20%) relapsed to drinking alcohol after a median of 15 months (range 2-18), one of whom had fulfilled the 6-month abstinence prior to LDLT (1/11) and two of whom had not (2/4). Younger age was a significant predictor of post-transplant relapse. Though the difference in relapse was not statistically significant (P = 0.154) between those recipients who had achieved 6 months of abstinence prior to transplant and those who had not, the authors concluded that a 6-month abstinence period prior to LDLT was likely useful in preventing post-transplant relapse.
In 2013, Park and colleagues published the outcomes of LDLT for ALD from the same single, high volume Korean center (Park et al., 2013) . Of 789 adult-to-adult LDLT performed at the institution between 1997 and 2004, only 18 patients underwent living donor transplantation for a solitary diagnosis of ALD. These 18 recipients were overwhelmingly male (94.4%) with an average age of 52 years and a median pre-transplant abstinence period of 16 months (range 2-48). The majority of patients (72.2%) received single lobe grafts. One-year patient survival was 100% and five-year survival was 87.8%. Of the 18 recipients transplanted for ALD, 4 did not meet the 6-month abstinence rule prior to transplant. Again, three patients (16.7%) relapsed; 1/14 patients who achieved 6 months of abstinence pre-transplant and 2/4 patients who did not achieve 6 months of abstinence (P = 0.097). Younger age was again a significant predictor of relapse in this analysis. Two patients died during the surveillance period, and both of these patients had relapsed to alcohol abuse. The authors reached a similar conclusion to the one they had come to in their earlier publication that a 6-month abstinence period prior to transplant was likely beneficial in preventing relapse.
A 2014 study published by the same group (Ahn et al., 2014 ) reviewed the outcomes of LDLT for ALD in recipients from 2001 to 2010. A total of 2196 patients underwent LDLT during this study period, with 126 (5.7%) transplanted for ALD. Again, the recipients were predominantly male (88.9%) with an average age of 51 years and 88% received single lobe grafts. One-year patient survival was 100%, fiveyear survival was 87.8%, and ten-year survival was 83.7%. Twenty one of 126 recipients (16.7%) did not have 6 months of abstinence from alcohol prior to transplant. About 10 patients (7.9%) were identified as having some amount of alcohol relapse after transplantation; 6 of these patients had observed the 6-month abstinence rule prior to transplant (6/105, 5.7%) and 4 had not (4/21, 19%, P = 0.11). Of the four cases of recipient mortality associated with alcohol relapse, two had observed the abstinence rule and two had not. Recipient age was not found to be associated with alcohol relapse or outcome in this study.
The three aforementioned studies were conducted by the same, single Korean center and therefore include overlapping patient populations.
Interestingly, despite the increase in volume of patients who underwent LDLT for ALD over the evolution of these studies, the conclusion remained the same: there was no significant difference in outcome or relapse rates between the patients who achieved 6 months of abstinence prior to transplant compared with those who did not. The 6-month abstinence rule does not seem to be operative in that transplant program.
The final two studies are a pair of studies from Egawa and colleagues (Egawa et al., 2014a, b) that examined risk factors for alcohol relapse (Egawa et al., 2014a) and high risk alcohol relapse (Egawa et al., 2014b) in recipients undergoing liver transplantation for ALD at multiple centers throughout Japan. The study cohort for both papers consisted of 195 subjects, the majority of whom (187) underwent LDLT. Consequently, the LDLT cohort was not analyzed separately but does represent the majority of the data presented. Survival rates at 1, 5 and 10 years were 82.5%, 78.4% and 50.4% for the entire cohort. The incidence of alcohol consumption after transplant in this cohort was 22.9%. For patients who remained abstinent at 18 months following transplant, 1-year survival was 100%, 5-year survival was 96.4% and 10-year survival was 73.8%. However, in patients who relapsed within 18 months of transplant, 1-year survival was 100%, 5-year survival was 89.5% and 10-year survival was 21.9% (P = 0.01).
The first study examined risk factors for alcohol consumption after transplant (Egawa et al., 2014a) , and found the following risk factors significantly impacted post-transplant alcohol consumption: a history of treatment for psychiatric condition before transplant (P < 0.01), no marital history (P = 0.04), non-compliance with clinic visits following transplantation (P < 0.01), and smoking after transplantation (P < 0.01). The authors also found that the relapse rate was 50% for patients who received livers from their parents, 34.5% for patients who received livers from their siblings, 13.3% for patients who received livers from their spouses, 19.7% for patients who received livers from their sons/daughters, and 14.3% for patients who received domino or deceased donor livers, but these differences did not reach statistical significance (P = 0.07). There was no significant impact of 6-month pre-transplant abstinence on post-transplant outcomes.
The next study in this pair examined predictors of harmful relapse after transplant, defined as a degree of alcohol consumption that caused alcohol-related damage to the graft. Of the 32 patients who relapsed, 24 did so within 18 months of transplantation and harmful relapse occurred in 18 of these 24 recipients. All of these 18 patients had lab abnormalities, 5 had abnormalities on biopsy pathology and 1 had associated psychiatric abnormalities. At 1 year after transplant, the survival rates were 95.4% for abstinent patients, 83.3% for patients with non-harmful relapse, and 94.1% for patients with harmful relapse, while at 5 years after transplant, the survival rates were 91.9%, 83.3% and 74.2% for these groups, respectively (Egawa et al., 2014b) .
LDLT FOR ALD-EXPERIENCE AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (2003-2015)
The University of California, San Francisco (UCSF) has been performing LDLT since 1992 and a total of 316 adult-to-adult LDLT have been completed through 2016. Recipients with appropriate disease severity and etiology are educated about the LDLT program at our institution and encouraged to reach out to any potential donors they may have. The recipient evaluation for LDLT is the same as for patients awaiting deceased donor liver transplantation and includes a comprehensive medical and psychosocial evaluation. Our institutional criteria are as follows: patients with a history of alcohol use or abuse must provide documented evidence of abstinence for a minimum of 6 months, undergo a multidisciplinary assessment of their support network that is the same as patients with other etiologies of liver disease, and participate in some form of rehabilitation. Illicit drug users must be drug free for 1 year; all substance abusers must sign a substance avoidance contract and consent to periodic, random drug screening.
Between 2003 and 2016, our center performed 136 adult-toadult LDLT, and a total of 22 patients underwent LDLT for ALD. In 14 patients (63.6%), this was the sole diagnosis and in 8 patients there was concomitant Hepatitis C (HCV) infection (Table 1 ). The mean age of patients undergoing LDLT for ALD (n = 22) was 55.5 years, 60% were men, and the mean MELD was 15.7. Seventy seven percent of these patients had ascites prior to LDLT, 73% had a history of prior drug use, and 41% had a history of prior tobacco use. The majority of patients received grafts from relatives (Table 2 ) and (73%) received right lobe grafts with an average graft volume of 687.5 ml as measured by volume displacement. The post-operative outcomes are summarized in Table 3 ; the average length of initial hospital stay was 14 days and 68% of patients required additional surgery at some point following transplant. A total of 6 patients lost their grafts, including 3 patients who died with a functioning graft. A total of 4 patients died. One patient relapsed to alcohol consumption, one patient resumed tobacco use, and one patient was lost to clinical follow up for approximately 18 months after LDLT.
A comparison of patients undergoing LDLT for ALD and recipients who underwent LDLT for other indications is shown in Tables 4 and 5 . The only significant difference in recipient demographics (Table 4) was a slightly greater height in ALD recipients (176.6 vs. 167.8 cm, P = 0.03). More non-ALD patients received left lobe grafts (51.3% vs. 27.3%, P = 0.035), but there was no significant difference in graft function, length of stay, or biliary complications between groups (Table 5) . ALD recipients more frequently required subsequent surgery (68.2% vs. 37.7%, P = 0.008). Of the 22 patients who underwent LDLT for ALD, 14 were transplanted for a primary diagnosis of ALD and 8 were transplanted with concomitant diagnoses of HCV. Of the 14 ALD primary patients, 8 (57%) required subsequent operations while 7 of the 8 (88%) of patients transplanted with concomitant HCV infection required subsequent operations.
At both one and 5 years there was no difference in patient survival (Fig. 1) or graft survival (Fig. 2) between the two groups.
DISCUSSION
The paucity of literature available on the outcomes of LDLT for ALD is striking; unsurprisingly, the majority of data is from Asian countries where LDLT is the standard for liver transplantation. Though there are five studies presented in this review (Hwang et al., 2006; Park et al., 2013; Ahn et al., 2014; Egawa et al., 2014a, b) , these results actually only represent the outcomes from one center in Korea and a collection of centers in Japan. The existing data on LDLT for ALD demonstrates that outcomes are acceptable and that pre-transplant abstinence does not necessarily impact post-transplant relapse.
Our data from UCSF confirms previous reports that excellent outcomes after LDLT can be obtained in the setting of ALD, with no difference in patient survival compared with non-ALD recipients. The LDLT recipients with ALD received larger grafts than our non-ALD recipients which is likely a result of both the size and gender difference, in addition to the greater proportion of right lobe grafts used in ALD recipients; ALD patients were 60% men with an average BMI of 27.3. ALD historically has been concentrated in men, though it may be a diagnosis that is increasing in female patients. The rate of relapse in the UCSF patient population was quite lowthree patients returned to alcohol (one), smoking (one) and lost to clinical follow up (one). Our program, like most others, requires a brief period of pre-transplant abstinence for patients receiving deceased as well as living donor transplantation.
Reoperation was significantly more common in ALD recipients compared with non-ALD recipients. This may have been the result of using more right lobe grafts; of the 15 ALD recipients who required reoperation, 12 were right lobe recipients. Multiple ducts are more common with right lobe than left lobe grafts, which can lead to increased biliary complications. Indeed, biliary leak or stricture was the indication for reoperation in 6 of 12 right lobe recipients requiring additional operations compared with 1 of 3 left lobe recipients.
Though the data reviewed and presented here supports the use of LDLT for ALD, these studies do not address the utility of LDLT for fulminant liver failure due to acute alcoholic hepatitis. Live donor transplants are done at our institution rarely for fulminant liver failure of other etiologies (due to the ease of obtaining cadaveric grafts for status 1 patients), but one would anticipate good outcomes with LDLT just as in recipients of many etiologies. Singal and Kamath published a recent thought piece in 2017 that explored the idea of LDLT for alcoholic hepatitis (Singal and Kamath, 2017) . The concerns outlined by the authors included the high MELD in fulminant alcoholic hepatitis patients and the increased risk of infection that is well established in patients with alcoholic hepatitis. The decision to use a live donor under circumstances of fulminant alcoholic hepatitis is likely to be more about the outcome after transplant than concern of the donor source.
Finally, as the use of LDLT for ALD becomes more widespread, we would advocate for diligent follow up and standardization of classifying return to alcohol consumption or other substance use following transplant. DiMartini et al. described patterns of alcohol consumption after transplant that may be a useful way to classify post-transplant consumption moving forward: complete abstinence, fluctuating low level of use, early onset rapidly accelerating moderate use, steady increase to moderate use after 3 years post-transplant, and early onset continuously heavy use (DiMartini et al., 2010) . While these definitions include criteria for amount of alcohol consumed and timing of heaviest use, they do not address return to associated substances such as tobacco, or clinical follow up. These issues are important for all LT recipients, but especially for those with a history of substance abuse. Because relapse produces such a visceral response in discussions of LT for ALD, it will be critical to provide honest and standard reports of post-transplant relapse to ensure transparency in the LDLT for ALD literature moving forward.
CONCLUSION
The data that has been published on LDLT for ALD represents the experience of a single center in Korea, a collection of centers in Japan, and now a single center in the United States. It appears that LDLT for ALD results in excellent patient outcomes with one and 5-year survival rates ranging from 82% to 100% and 78% to 87%, respectively. These outcomes match those of recipients with other diagnosis. Rates of alcohol relapse following transplant appear to be low, ranging from 7% to 23%, and 6-month abstinence periods prior to LDLT for ALD do not appear to have a significant impact on relapse. However, the most definitive conclusion that can be drawn from this review is that the data on LDLT for ALD is extremely limited and further study is imperative. 
